Kiesecker, C.; Zitron E.; Lück S.; Bloehs R.; Scholz E.P.; Kathöfer S.; Thomas D.; Kreye V.A.; Katus H.A. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.. Naunyn Schmiedebergs Arch Pharmacol. 2004, 370 (6): 423–35. PMID 15599706. doi:10.1007/s00210-004-0976-8.
Hedley, P. L., Jørgensen, P., Schlamowitz, S., Moolman-Smook, J., Kanters, J. K., Corfield, V. A.; Christiansen, M. The genetic basis of Brugada syndrome: A mutation update.. Hum. Mutat. 2009, 30 (9): 1256–1266. PMID 19606473. doi:10.1002/humu.21066.
Rolf, S.; Bruns, H.J.; Wichter, T.; Kirchhof, P.; Ribbing, M.; Wasmer, K.; Paul, M.; Breithardt, G.; Haverkamp, W. The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol.. Eur Heart J. 2003, 24 (12): 1104–1112. PMID 12804924. doi:10.1016/s0195-668x(03)00195-7.
nih.gov
ncbi.nlm.nih.gov
Hinse, C.; Stöckigt, J. The structure of the ring-opened N beta-propyl-ajmaline (Neo-Gilurytmal) at physiological pH is obviously responsible for its better absorption and bioavailability when compared with ajmaline (Gilurytmal).. Pharmazie. 2000, 55 (7): 531–2. PMID 10944783.
Kiesecker, C.; Zitron E.; Lück S.; Bloehs R.; Scholz E.P.; Kathöfer S.; Thomas D.; Kreye V.A.; Katus H.A. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.. Naunyn Schmiedebergs Arch Pharmacol. 2004, 370 (6): 423–35. PMID 15599706. doi:10.1007/s00210-004-0976-8.
Hedley, P. L., Jørgensen, P., Schlamowitz, S., Moolman-Smook, J., Kanters, J. K., Corfield, V. A.; Christiansen, M. The genetic basis of Brugada syndrome: A mutation update.. Hum. Mutat. 2009, 30 (9): 1256–1266. PMID 19606473. doi:10.1002/humu.21066.
Rolf, S.; Bruns, H.J.; Wichter, T.; Kirchhof, P.; Ribbing, M.; Wasmer, K.; Paul, M.; Breithardt, G.; Haverkamp, W. The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol.. Eur Heart J. 2003, 24 (12): 1104–1112. PMID 12804924. doi:10.1016/s0195-668x(03)00195-7.
